Jeanette Jakobsson
India’s Supreme Court rejects patent plea by Novartis for the cancer drug Glivec
By Jeanette Jakobsson | Posted on April 18, 2013
For years, India did not offer any patent protection for chemical compounds, but was obliged to do this after joining the World Trade Organization. In 2005, the patent protection act therefore was amended to also include such compounds, but only if they proved significant clinical efficacy enhancements over already patented compounds, Section 3(d) of the Indian...
Poverty versus patenting in India – round two
By Jeanette Jakobsson | Posted on November 22, 2012
Earlier this year the first compulsory license, regarding the anti-cancer drug Sorafenib, was granted in India. (See previous blog post.) The compulsory license was granted inter alia on the ground that the patented invention was not available to the public at a reasonable affordable price. The battle towards affordable medicaments in India continues. In a...
Tags: compulsory license, drug patents, India, Pharmaceuticals
India Grants the First Compulsory License
By Jeanette Jakobsson | Posted on March 30, 2012
The Compulsory License Application No. 1 of 2011, the first of its kind in the history of the Indian Patents Act 1970, concerns the anti-cancer drug Sorafenib, where the patentee is Bayer Corporation and the applicant for a compulsory license is Natco Pharma Limited. The anti-cancer drug Sorafenib, sold under the brand name NEXAVAR, is...
Recent contributors
Partner, European Patent Attorney
Senior Associate, Attorney at Law
Partner, Attorney at Law, Group Vice President
Partner, Attorney at Law, Business Area Manager
Senior Counsel, European Patent Attorney
